PR94854

MOUNTAIN VIEW, Calif., Mar. 7, 2022 /PRNewswire=KYODO JBN/--

-- Hires will help to expand Turn's commercial reach, protect its unique ERA

Platform technology

Turn Biotechnologies, a cell rejuvenation company developing novel mRNA

medicines to cure now-untreatable, chronic, age-related conditions, today

announced the addition of global expertise in partnership development and

intellectual property protection.

Turn has hired two executives with deep experience that will help to maximize

the company's commercial reach through the development of international

partnerships and preserve its value by protecting its proprietary science,

including its break-through ERA Platform technology.

Marie-Louise Bots, an executive with broad global expertise and a record of

strategic transformation in Fortune 500 corporations and venture-backed firms,

was named senior vice president of corporate and business development. She will

oversee Turn's efforts to develop strategic partnerships with healthcare,

insurance and financial companies, around the world.

Throughout her career, she has provided strategic leadership to companies such

as Rotterdam-based Aon Risk Solutions, where she served as chief commercial

officer and transformed the commercial organization, developing and driving its

strategy.

She founded Philips Royal Electronics' Skincare Division and drove its embrace

of innovative technology while creating partnerships and managing the

division's acquisitions and joint ventures. At Philips, she also accelerated

critical changes in the Oral Healthcare Division by acquiring Sonicare.

Bots has a degree in Economics from Fontys University of Applied Sciences in

Eindhoven, Netherlands, and has studied at Erasmus University in Rotterdam and

Babson College in Boston.

Dr. Devang Thakor, a corporate and patent attorney, has been named vice

president of intellectual property and legal. Thakor granted more than 130

pharmaceutical and biotechnology patents in a decade as a U.S. patent examiner,

including four years as a primary examiner, and has advised Global 500

companies, international startups, venture capital firms and universities on

intellectual property and business issues.

Thakor's hands-on experience at the U.S. Patent and Trademark Office provides

novel and practical perspectives on the processes companies must follow to

protect their intellectual property. His work with companies in North America

and Asia gives him unique understanding of the nuances that must be negotiated

as they enter markets with diverse intellectual property protection

regulations.

He also brings technical expertise to Turn's intellectual property strategy,

having developed nucleic acid delivery and regenerative medicine technologies

in postdoctoral fellowships at Harvard Medical School, the VA Boston Healthcare

System and Kyoto University.

"The expertise that Marie-Louise and Devang bring to Turn is critical to our

long-term growth strategy," said Turn CEO Anja Krammer. "Our cutting-edge

science has the potential to change the lives of millions of people afflicted

with age-related conditions that medicine cannot treat today. Their experience

will help to grow and protect our value for investors, while speeding our

commercial reach through global business partnerships."

ABOUT TURN BIOTECHNOLOGIES

Turn is a pre-clinical-stage company focused on repairing tissue at the

cellular level. The company's proprietary mRNA platform technology, ERA™,

combats the effects of aging in the epigenome, thus restoring optimal gene

expression and enabling cells to function as vigorously as when they were

younger. This restores the cells' ability to prevent or treat disease and heal

or regenerate tissue and will help to fight incurable chronic diseases.

Turn's technology provides a platform from which to attack a variety of now

incurable chronic diseases. The company is currently completing pre-clinical

research on tailored therapies targeting indications in dermatology and

immunology, as well as developing therapies for ophthalmology, osteo-arthritis

and the muscular system. For more information, visit: www.turn.bio .

For more information contact:

Jim Martinez, rightstorygroup, jim@rightstorygroup.com or +1-312-543-9026

SOURCE: Turn Biotechnologies